NPCE

Neuropace, Inc.

14.75 USD

Last updated Sep 5, 10:54 UTC

Yesterday HIGH

$14.9

Yesterday LOW

$14.47

52w HIGH

$19.6

52w LOW

$8.88

EPS

-0.18

PE

-81.94

Next Earnings

Nov 3, 2026

Overview News Government Trades Fundamentals

Neuropace, Inc. stock is up 6.12% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 September’s closed higher than August.

Benzinga Newsdesk

Tue Jul 28, 2026

Neuropace shares are trading lower after the company announced it received communication from the FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form.
Benzinga Newsdesk

Tue Jul 28, 2026

NeuroPace Asked To Submit Submission Issue Request By FDA For Its RNS System To Include Patients With Antiseizure Medication-Resistant Idiopathic Generalized Epilepsy; FDA Indicated PMA Supplment Not Approvable In Current Form

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company’s
Benzinga Newsdesk

Thu Jul 23, 2026

Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

Mizuho analyst Anthony Petrone initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Price Target of $22.
Benzinga Newsdesk

Fri May 29, 2026

NeuroPace To Highlight Expanding Role Of Responsive Neuromodulation In Epilepsy Care In 2026 ASSFN Meeting

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations----NeuroPace to engage neurosurgeon community through
Benzinga Newsdesk

Fri May 15, 2026

HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $19 to $20.
Benzinga Newsdesk

Wed May 13, 2026

Neuropace shares are trading lower. The company reported Q1 financial results.
Benzinga Insights

Tue May 12, 2026

NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga Newsdesk

Tue May 12, 2026

NeuroPace Raises FY2026 Sales Guidance from $98.000M-$100.000M to $99.000M-$101.000M vs $98.910M Est

NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $98.000 million-$100.000 million to $99.000 million-$101.000 million vs $98.910 million estimate.
Benzinga Newsdesk

Tue May 12, 2026

NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.04 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026

NCLH $15.56 USD

TGTX $56.00 USD

ONON $27.99 USD

NTLA $12.75 USD

ETH ETH $23.42 USD

NFLX $78.29 USD